This HTML5 document contains 79 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
n22http://linked.opendata.cz/resource/drugbank/drug/DB00449/identifier/kegg-drug/
dctermshttp://purl.org/dc/terms/
n18http://linked.opendata.cz/resource/drugbank/drug/DB00449/identifier/drugbank/
n10http://linked.opendata.cz/resource/AHFS/
foafhttp://xmlns.com/foaf/0.1/
n5http://linked.opendata.cz/resource/drugbank/company/
n23http://linked.opendata.cz/resource/drugbank/drug/DB00449/identifier/national-drug-code-directory/
n28http://linked.opendata.cz/resource/drugbank/mixture/
n26http://bio2rdf.org/drugbank:
n17http://linked.opendata.cz/resource/drugbank/drug/DB00449/identifier/chemspider/
admshttp://www.w3.org/ns/adms#
n12http://linked.opendata.cz/resource/drugbank/drug/DB00449/identifier/chebi/
n25http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
n19http://linked.opendata.cz/resource/drugbank/drug/DB00449/identifier/wikipedia/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n27http://linked.opendata.cz/resource/drugbank/medicinal-product/
n20http://linked.opendata.cz/resource/drugbank/drug/DB00449/identifier/pharmgkb/
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n8http://www.drugs.com/cdi/
n14http://www.rxlist.com/cgi/generic2/
n16http://linked.opendata.cz/resource/drugbank/drug/DB00449/identifier/kegg-compound/
n4http://linked.opendata.cz/resource/drugbank/property/
n13http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/
xsdhhttp://www.w3.org/2001/XMLSchema#
n21http://linked.opendata.cz/resource/drugbank/drug/DB00449/identifier/pubchem-compound/
n15http://linked.opendata.cz/resource/drugbank/drug/DB00449/identifier/pubchem-substance/
n9http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00449
rdf:type
n3:Drug
n3:description
Dipivefrin is a prodrug of adrenaline, which is used to treat glaucoma. It is available as ophthalmic solution (eye drops).
n3:group
approved
n3:indication
Dipivefrin is a prodrug which is used as initial therapy for the control of intraocular pressure in chronic open-angle glaucoma.
n3:manufacturer
n5:271B51F0-363D-11E5-9242-09173F13E4C5 n5:271B51F1-363D-11E5-9242-09173F13E4C5 n5:271B51EE-363D-11E5-9242-09173F13E4C5 n5:271B51EF-363D-11E5-9242-09173F13E4C5
owl:sameAs
n25:DB00449 n26:DB00449
dcterms:title
Dipivefrin
adms:identifier
n12:4646 n15:46504716 n16:C06963 n17:2994 n18:DB00449 n19:Dipivefrin n20:PA449364 n21:3105 n22:D02349 n23:0023-9208-10
n3:mechanismOfAction
Dipivefrin is a prodrug with little or no pharmacologically activity until it is hydrolyzed into epinephrine inside the human eye. The liberated epinephrine, an adrenergic agonist, appears to exert its action by stimulating α -and/or β<sub>2</sub>-adrenergic receptors, leading to a decrease in aqueous production and an enhancement of outflow facility. The dipivefrin prodrug delivery system is a more efficient way of delivering the therapeutic effects of epinephrine, with fewer side effects than are associated with conventional epinephrine therapy.
n3:packager
n5:271B51EC-363D-11E5-9242-09173F13E4C5 n5:271B51ED-363D-11E5-9242-09173F13E4C5 n5:271B51EA-363D-11E5-9242-09173F13E4C5 n5:271B51EB-363D-11E5-9242-09173F13E4C5 n5:271B51E8-363D-11E5-9242-09173F13E4C5 n5:271B51E9-363D-11E5-9242-09173F13E4C5
n3:synonym
Dipivefrina Dipivefrinum Dipivefrin Dipivalyl Epinephrine Dipivéfrine (+-)-4-[1-Hydroxy-2-(methylamino)ethyl]-O-phenylene divavalate 4-[1-Hydroxy-2-(methylamino)ethyl]-O-phenylene divavalate Pro-Epinephrine 1-(3',4'-Dipivaloyloxyphenyl)-2-methylamino-1-ethanol
n3:toxicity
Oral LD<sub>50</sub> in rat is 183 mg/kg.
n9:hasAHFSCode
n10:52-24-00
n3:mixture
n28:271B51E7-363D-11E5-9242-09173F13E4C5
n3:salt
n3:synthesisReference
Hussain, A. and Truelove, J.E.; U.S. Patents 3,809.714; May 7,1974; and 3,839,584; October 1, 1974; both assigned to Inter Rx Research Corp. Henschler, D., Wagner, J. and Hampel, H.; US. Patent 4,085,270; April 18,1978; assigned to Chemisch-Pharmazeutische Fabrik Adolf Klinge & Co. (W. Germany).
foaf:page
n8:dipivefrin.html n13:pro1356.shtml n14:dipivefrin.htm
n3:IUPAC-Name
n4:271B51F7-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B51FD-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B51FC-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B51F9-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B51FA-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B51FB-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B51F5-363D-11E5-9242-09173F13E4C5 n4:271B520D-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B51F3-363D-11E5-9242-09173F13E4C5 n4:271B520F-363D-11E5-9242-09173F13E4C5 n4:271B51F6-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B51F4-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Acceptor-Count
n4:271B5203-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B5204-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B51FE-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B51FF-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B5201-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B5200-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B5202-363D-11E5-9242-09173F13E4C5
n3:absorption
Well absorbed following occular administration.
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
52365-63-6
n3:category
n3:containedIn
n27:271B51F2-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n4:271B5209-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B520B-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B520C-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n4:271B520E-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B5208-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B5207-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B520A-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B51F8-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B5205-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B5206-363D-11E5-9242-09173F13E4C5